J. Devlin

Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA.

M. Knowles, A. Keen, J. Devlin, 1994, Oncogene.

High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.

H. Gabra, M. Knowles, P. Elder, 1996, British Journal of Cancer.

ited in an autosomal dominant pattern with a high degree of penetrance

W. Noll, J. Devlin, D. Wurster-Hill, 2006 .

Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci.

Patricia A. Elder, M. Knowles, T. Habuchi, 1995, Oncogene.

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.

M. Williamson, Patricia A. Elder, M. Knowles, 1995, Human molecular genetics.

Fragile sites and high-resolution chromosome studies in multiple endocrine neoplasia type 2A.

S. H. Gibson, R. Erbe, W. Noll, 1988, Cancer genetics and cytogenetics.

A cytogenetic study of familial medullary carcinoma of the thyroid.

W. Noll, J. Devlin, D. Wurster-Hill, 1986, Cancer research.

Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci.

Patricia A. Elder, T. Habuchi, J. Devlin, 1995, Oncogene.